Erratum
After publication of the original article [1], it came to the authors’ attention that there was an error in the number of male and female participants. The correct number is 90 male and 88 female, not 89 male and 89 female as originally reported.
This error was present in the Methods section of the abstract and in Table 1.
Table 1.
The baseline characteristics of the study participants
| Mean | Std. Deviation | |
|---|---|---|
| Age | 64.2 | 9.2 |
| Disease duration | 6.8 | 4.5 |
| Sex (male/female) n | 90 | 88 |
| Wearing off (+/−) n | 58 | 120 |
| Dyskinesia (+/−) n | 42 | 136 |
| Levodopa mg | 344.1 | 202.8 |
| Levodopa (+/−) n | 154 | 24 |
| Dopamine agonist levodopa equivalent dose (mg) [12] | 166.3 | 121.1 |
| Total levodopa equivalent dose (mg) [12]a | 592.0 | 317.6 |
| Unified Parkinson’s Disease Rating Scale | ||
| Part I | 0.7 | 1.2 |
| Part II | 5.6 | 3.9 |
| Part III | 15.7 | 8.4 |
| Part IV | 1.7 | 2.2 |
| Total | 23.7 | 11.8 |
| Modified Hoehn and Yahr stage | 2.1 | 0.6 |
| Parkinson’s disease Questionnaire-39 | ||
| Mobility | 10.4 | 9.1 |
| Activities of daily living | 5.2 | 5.1 |
| Emotional well-being | 6.0 | 4.4 |
| Stigma | 3.2 | 2.8 |
| Social support | 1.4 | 1.9 |
| Cognitions | 4.0 | 3.0 |
| Communication | 1.7 | 2.2 |
| Body discomfort | 2.5 | 2.6 |
| Total | 34.4 | 24.2 |
anot including istradefylline and zonisamide
Footnotes
The online version of the original article can be found under doi:10.1186/s12883-016-0589-0.
Reference
- 1.Yoritaka A, Abe T, Ohatsuka C, et al. A randomized double-blind multi-center trial of hydrogen water for Parkinson’s disease: protocol and baseline characteristics. BMC Neurol. 2016;16:66. doi: 10.1186/s12883-016-0589-0. [DOI] [PMC free article] [PubMed] [Google Scholar]